Current recommandations for the treatment of iron deficiency anemia;Recommandations actuelles pour le traitement de l'anémie ferriprive

Revue Medicale Suisse

Volumn 3, Issue 105, 2007, Pages 874-880

  Schaefer, Roland M ^a   Huch, Renate ^b   Krafft, Alexander ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; IRON; IRON SACCHARATE; RECOMBINANT ERYTHROPOIETIN;

DRUG ABSORPTION; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; REVIEW;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; EPOETIN ALFA; ERYTHROCYTE COUNT; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; SUCROSE; SWITZERLAND; TRANSFERRIN;

EID: 34247492496     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. * Hercberg S, Preziosi P, Galan P. Iron deficiency in Europe. Public Health Nutr 2001;4:537-45.
2. Kaltwasser JP, Gottschalk R. Erythropoietin and iron. Kidney Int 1999;69(Suppl.):S49-S56.
3. Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999;69(Suppl.):S44-S8.
4. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001;60:2406-11.
5. ** European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working party for european best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14 (Suppl. 5):1-50.
6. Kosch M, Schaefer RM, Bahner U. Substitution mit Mineralstoffen und Spurenelementen. Internist Berlin 2002;43:1299-307.
7. Kosch M, Schaefer RM. Indikation und praktische Durchführung der parenteralen Eisentherapie. Wien Klin Wochenschr 2003;115:380-4.
8. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-44.
9. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-91.
10. Schaefer RM, Schaefer L. Management of iron substitution during rhEPO therapy in chronic renal failure patients. Erythropoiesis 1992;3:71-5.
11. Dejaco C, Gasche C. Anämie bei chronisch entzündlichen Darmerkrankungen : Ein oft unterschätztes Problem. Dtsch Med Wochenschr 2002;127:805.8.
12. Gasche C, Waldhoer T, Feichtenschlager T, et al. Austrian inflammatory bowel diseases study group. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001;96:2382-7.
13. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997;126:782-7.
14. Milman N, Bergholt T, Byg KE, Eriksen L, Graudal N. Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation. Acta Obstet Gynecol Scand 1999;78:749-57.
15. Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet Gynecol 2001;184:662-7.
16. Perewusnyk G, Huch R, Huch A, Breymann C. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. Br J Nutr 2002;88:3-10.
17. Krafft A, Breymann C, Quack K, Huch R. Severe anemia in the Puerperium : Selective use of recombinant human erythropoietin (rhEPO) and iron sucrose in the avoidance of blood transfusion. Transfusion Alternatives in Transfusion Medicine 2002;4(Suppl. 2):75-6.
18. * Fishbane S. Safety in iron management. Am J Kidney Dis 2003;41(Suppl. 5):18-26.
19. FDA. Adverse event reporting system (AERS), freedom of information (FOI) Report, from: 01-Nov-1997 to: present
20. Macdougall I, Bailie G, Richardson D, et al. Worldwide safety profile of iron sucrose injection (Venofer): Analysis of 1,004,477 patients from 1992 to 2001. Presented at the ASN World congress of nephrology, Oct. 13-17, 2001, San Francisco, CA.